Find care
Spravato vs Ketamine: What Actually Changes Your Choice?
Spravato vs ketamine is a comparison between a specific FDA-approved esketamine nasal spray and several other ketamine treatment formats. Spravato is administered in a certified healthcare setting for approved adult depression indications. Other ketamine treatment for depression is off-label, and compounded ketamine products are not FDA-approved.
The most useful choice is not simply “nasal spray or infusion.” Ask what product you would receive, where it would be given, how you would be monitored and what the entire course would cost. Your clinician needs to decide which options are appropriate.
Compare the treatment you are actually being offered
| Feature | Spravato | Other clinic-based ketamine | At-home compounded ketamine |
|---|---|---|---|
| Product | Branded esketamine nasal spray | Product and route vary; ask the clinic | Compounded product; route varies by program |
| Depression approval | Specific FDA-approved adult indications | Ketamine psychiatric use is off-label | No FDA-approved psychiatric indication for the compounded product |
| Setting | REMS-certified healthcare setting | Clinic; verify its specific monitoring process | Home; ask exactly what support is present |
| Onsite professional | Required healthcare setting and monitoring | Verify staff, equipment and supervision | Do not assume an onsite clinician is included |
| Insurance | Check your plan's Spravato policy and clinic benefits | Check the exact diagnosis, procedure and policy | Confirm directly; do not assume reimbursement from a superbill |
| Comparison trap | Treating a low drug copay as the full bill | Treating all infusions as one standardized service | Treating a sitter or remote support as clinical monitoring |
Sources: current FDA Spravato Medication Guide, FDA compounded-drug information and the FDA's historical ketamine warning, linked from its current risk-alert index.
Esketamine and ketamine are related, but the services are not interchangeable
Esketamine is one of the two mirror-image forms in racemic ketamine. The brand Spravato refers to a particular esketamine product and its approved use conditions. A compounded nasal spray labeled ketamine is not automatically Spravato, even though both can be sprayed into the nose.
Likewise, research on a clinic infusion cannot simply be used as proof for a company's oral home program. The route, dose, patient selection, monitoring, support and study design may differ. Ask a provider which evidence applies to its own treatment model rather than accepting a general “ketamine works” claim.
Approval is a meaningful difference, not a personal recommendation
Spravato's current approved uses include adult treatment-resistant depression, with or without an oral antidepressant. The MDD indication involving suicidal thoughts or actions requires an oral antidepressant. The FDA guide sets out its limitations and risks.
Off-label prescribing means a clinician uses a medicine outside its approved labeling. It does not mean every off-label treatment is prohibited, and it also does not mean the FDA evaluated that particular use. Compounded products have a further distinction: the products themselves are not FDA-approved. Do not merge those two concepts.
For the evidence question, see ketamine therapy for depression.
Monitoring matters as much as the route
Ask who is physically present, what they monitor and what happens if you have a serious reaction. A video check-in, text support, an adult companion and an onsite healthcare professional are different forms of help.
Spravato requires at least two hours of post-administration monitoring in its certified setting. For another clinic, request its written monitoring and discharge procedures. For a home program, ask whether any clinician watches the session live, what the required companion must do and how an emergency is handled. The FDA's historical warning specifically discussed added risks when no healthcare professional is onsite.
These questions do not produce a universal safety score. They make the actual service visible before you pay.
Compare full-course costs, not a dose or a monthly ad
The total may include evaluation, medicine, administration, observation, support appointments, ongoing treatment and travel. Insurance can cover some components and exclude others. Financing can spread payment without lowering the total.
Ask each provider for a quote on the same planning period. For example, compare what you would owe over the first month and what happens after that period. If one quote covers a package and another lists each visit separately, write those differences next to the price.
Start with ketamine therapy cost, then use Spravato cost for the medicine-versus-observation breakdown. Coverage questions are in our insurance guide.
A practical way to narrow the discussion
| Your priority | What to ask next |
|---|---|
| An FDA-approved depression product | Ask a clinician whether Spravato fits your diagnosis and history |
| Onsite care throughout treatment | Ask a certified center or clinic about its monitoring, staffing and discharge process |
| Insurance access | Request a benefits check for the exact product and clinic before comparing cash prices |
| Staying at home | Discuss home-treatment risks and suitability first; then compare actual support and total program prices |
| Avoiding medicine-related dissociation | Ask about alternatives such as TMS and other appropriate care |
This table organizes questions. It does not screen or select treatment for you.
Before booking either option
Confirm the prescribing clinician's name and license, the product and pharmacy, the treatment setting, the monitoring plan, the full price and the refund terms. Tell the clinician about your diagnosis, medical history, previous treatment and all medicines and supplements. Do not change existing treatment on your own to meet a program's criteria.
For a clinic route, the Spravato review has a booking checklist. For home programs, our at-home ketamine comparison compares services and limitations without treating an affiliate relationship as a medical reason to choose one.
Sources and check date
Checked November 17, 2026 using FDA labeling, FDA compounding information and the historical FDA ketamine warning. This is a consumer comparison of documented treatment models, not a head-to-head clinical trial or a personalized treatment recommendation.